AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Exelixis Inc. (EXEL)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

34.06

-0.94 (-2.69%)

At close: Feb 18, 2025, 3:59 PM

34.20

0.41%

After-hours: Feb 18, 2025, 04:42 PM EST

undefined% (undefined)

Bid	34
Market Cap	9.53B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	1.76
PE Ratio (ttm)	19.35
Forward PE	n/a
Analyst	Buy

Ask	35
Volume	1,878,818
Avg. Volume (20D)	2,285,872
Open	35.11
Previous Close	35.00
Day's Range	34.01 - 35.37
52-Week Range	20.14 - 37.59
Beta	undefined

About EXEL

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CA...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 17, 2000

Employees 1,147

Stock Exchange NASDAQ

Ticker Symbol EXEL

Website https://www.exelixis.com

Full Company Profile

Analyst Forecast

According to 18 analyst ratings, the average rating for EXEL stock is "Buy." The 12-month stock price forecast is $38, which is an increase of 11.57% from the latest price.

Buy 61.11%

Hold 38.89%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Exelixis Inc. is scheduled to release its earnings on Apr 29, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

6 days ago

-0.03%

Exelixis shares are trading higher. Piper Sandler ... Unlock content with Pro Subscription

3 weeks ago

-5.13%

Exelixis shares are trading lower after Oppenheimer downgraded the stock from Outperform to Perform and cut its price target from $41 to $33.

News

21 hours ago · zacks.com

Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?

EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and impressive pipeline progress. We are optimistic about the stock as we believe there is room for further growth.

1 day ago · zacks.com

International Markets and Exelixis (EXEL): A Deep Dive for Investors

Explore Exelixis' (EXEL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

3 days ago · businesswire.com

Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating CABOMETYX® (cabozantinib) in combination with Opd...

4 days ago · zacks.com

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

1 week ago · zacks.com

EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus

Exelixis beats on Q4 earnings and sales as lead drug Cabometyx maintains momentum. The company reiterates its guidance for 2025.

6 days ago · seekingalpha.com

Exelixis: Cabozantinib Continues To Grow, Zanzalintinib Could Soon Follow

Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. EXEL's 2025 total revenue guidance is flat at $2.15B-$2.25B, although that doesn't model...

1 week ago · seekingalpha.com

Exelixis, Inc. (EXEL) Q4 2024 Earnings Call Transcript

Exelixis, Inc. (NASDAQ:EXEL ) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs & Investor Relations Mike Morr...

1 week ago · zacks.com

Exelixis (EXEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compa...

1 week ago · zacks.com

Exelixis (EXEL) Q4 Earnings and Revenues Top Estimates

Exelixis (EXEL) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.33 per share a year ago.

1 week ago · fool.com

Exelixis Posts 63.7% Profit Surge

Exelixis (EXEL -2.06%), a biopharmaceutical company specializing in oncology treatments, released its fourth-quarter 2024 financial results, revealing a substantial rise in both revenue and earnings. ...

Load More News